{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:17:12Z","timestamp":1787980632855,"version":"build-2784847793"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,7]]},"abstract":"<jats:p>Increased weight has been observed among treatment-na\u00efve-and-experienced people living with HIV initiating bictegravir (BIC) and dolutegravir (DTG). Here, we report changes in weight and body mass index (BMI) following switch to a BIC versus DTG-based regimen (DBR) through 144 weeks. This observational study collected demographics, clinical characteristics, weight, and BMI from virologically suppressed adults switched to BIC\/emtricitabine\/tenofovir alafenamide (TAF), emtricitabine\/TAF plus DTG, DTG\/abacavir\/lamivudine, DTG\/rilpivirine (RPV), and DTG\/lamivudine 2 years prior to switch through 144 weeks post-switch. Linear spline models were fit to estimate and compare the trajectories of weight and BMI changes observed pre-and-post-switch. Adjusted piecewise linear mixed-effects models were fit to examine factors associated with weight and BMI change pre-and-post-switch. At week 144, switching to BIC\/emtricitabine\/TAF versus a DBR were both associated with lower annualized weight gain post-switch (\u20100.88\u2009kg\/year vs \u22120.39\u2009kg\/year respectively, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.15). DTG plus emtricitabine\/TAF switches had the highest annualized weight gain (0.68\u2009kg\/year, 95% confidence interval: \u22120.32, 1.65) whereas, DTG\/RPV switches had the lowest annualized weight gain (\u20102.22\u2009kg\/year, 95% confidence interval: \u22123.69, \u22120.62) post-switch. DTG\/RPV and BIC\/emtricitabine\/TAF switches were the only groups with significantly lower annualized weight gain post-switch at week 144. Baseline BMI\u2005&lt;\u200518.5\u2009kg\/m<jats:sup>2<\/jats:sup> was associated with the highest annualized weight gain post-switch, whereas switching from protease inhibitors and self-report of dieting were associated with the lowest annualized weight gain post-switch. At week 144, switching to a BIC versus DBR were both associated with lower annualized weight gain post-switch among a large and diverse cohort of treatment-experienced people living with HIV.<\/jats:p>","DOI":"10.1097\/md.0000000000041728","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:03:56Z","timestamp":1743206636000},"page":"e41728","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Change in weight and BMI associated with switching to bictegravir\/emtricitabine\/tenofovir alafenamide versus a dolutegravir-based regimen among virologically suppressed adults living with HIV through 144 weeks"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-2225","authenticated-orcid":false,"given":"Charlotte-Paige","family":"Rolle","sequence":"first","affiliation":[{"name":"Orlando Immunology Center, Orlando, FL"},{"name":"Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Garrett","sequence":"additional","affiliation":[{"name":"Orlando Immunology Center, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Castano","sequence":"additional","affiliation":[{"name":"Orlando Immunology Center, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Orlando Immunology Center, Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Patel","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Hinestrosa","sequence":"additional","affiliation":[{"name":"Orlando Immunology Center, Orlando, FL"},{"name":"University of Central Florida College of Medicine, Orlando, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"DeJesus","sequence":"additional","affiliation":[{"name":"Orlando Immunology Center, Orlando, FL"},{"name":"University of Central Florida College of Medicine, Orlando, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250328","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R2-20250328","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment naive persons starting dolutegravir-based antiretroviral therapy.","volume":"70","author":"Bourgi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R3-20250328","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors.","volume":"33","author":"Eckard","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"R4-20250328","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/cid\/ciz853","article-title":"Weight gain associated with integrase stand transfer inhibitor use in women.","volume":"71","author":"Kerchberger","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R5-20250328","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/aid.2020.0197","article-title":"Weight and body mass index change after switching to integrase inhibitors or tenofovir alafenamide among women living with HIV.","volume":"37","author":"Lahiri","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R6-20250328","doi-asserted-by":"crossref","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","article-title":"Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy.","volume":"71","author":"Lake","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R7-20250328","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/QAD.0000000000001495","article-title":"Dolutegravir and weight gain: an unexpected bothering side effect?","volume":"31","author":"Menard","year":"2017","journal-title":"AIDS"},{"key":"R8-20250328","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/QAI.0000000000001525","article-title":"Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens.","volume":"76","author":"Norwood","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R9-20250328","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/apc.2022.0203","article-title":"Weight change when initiating, switching to, and discontinuing integrase strand transfer inhibitors in people living with HIV.","volume":"37","author":"Tieosapjaroen","year":"2023","journal-title":"AIDS Patient Care STDS"},{"key":"R10-20250328","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/03007995.2023.2239661","article-title":"Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.","volume":"39","author":"Tse","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"R11-20250328","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV.","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"R12-20250328","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/cid\/ciz410","article-title":"Do Integrase inhibitors cause weight gain?","volume":"70","author":"Wood","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R13-20250328","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials.","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R15-20250328","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence.","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R16-20250328","doi-asserted-by":"crossref","first-page":"e3902","DOI":"10.1093\/cid\/ciaa1073","article-title":"CYP2B6 genotype and weight gain differences between dolutegravir and efavirenz.","volume":"73","author":"Griesel","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R17-20250328","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/QAI.0000000000002447","article-title":"Metabolic changes associated with the use of integrase strand transfer inhibitors among virally controlled women.","volume":"85","author":"Summers","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R18-20250328","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QAD.0000000000002379","article-title":"No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV.","volume":"34","author":"Burns","year":"2020","journal-title":"AIDS"},{"key":"R19-20250328","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1089\/aid.2020.0287","article-title":"Changes in body mass index associated with antiretroviral regimen switch among treatment-experienced, virologically suppressed people living with HIV in the United States.","volume":"37","author":"Mounzer","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R20-20250328","doi-asserted-by":"crossref","first-page":"e0251205","DOI":"10.1371\/journal.pone.0251205","article-title":"Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants.","volume":"16","author":"Verboeket","year":"2021","journal-title":"PLoS One"},{"key":"R21-20250328","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/S2352-3018(23)00328-4","article-title":"Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.","volume":"11","author":"Byonanebye","year":"2024","journal-title":"Lancet HIV"},{"key":"R22-20250328","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(22)00094-7","article-title":"Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.","volume":"9","author":"Neesgaard","year":"2022","journal-title":"Lancet HIV"},{"key":"R23-20250328","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/cid\/ciac355","article-title":"Integrase strand transfer inhibitors are associated with incident diabetes mellitus in people with human immunodeficiency virus.","volume":"75","author":"O\u2019Halloran","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R24-20250328","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12879-024-09120-7","article-title":"The effect of a treatment switch to integrase Strand transfer inhibitor-based regimens on weight gain and other metabolic syndrome-related conditions.","volume":"24","author":"Maman","year":"2024","journal-title":"BMC Infect Dis"},{"key":"R25-20250328","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/QAD.0000000000002421","article-title":"Weight gain in people living with HIV switched to dual therapy: changes in body fat mass.","volume":"34","author":"Vizcarra","year":"2020","journal-title":"AIDS"},{"key":"R26-20250328","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"R27-20250328","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","article-title":"Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"key":"R28-20250328","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2018.7777","article-title":"Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"320","author":"LeBlanc","year":"2018","journal-title":"JAMA"},{"key":"R29-20250328","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jama.2022.7408","article-title":"Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults without known cardiovascular disease risk factors: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"328","author":"Patnode","year":"2022","journal-title":"JAMA"},{"key":"R30-20250328","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s10461-019-02503-x","article-title":"Behavioral and cardiovascular effects of a behavioral weight loss program for people living with HIV.","volume":"24","author":"Wing","year":"2020","journal-title":"AIDS Behav"},{"key":"R31-20250328","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s10461-019-02645-y","article-title":"Behavioral weight loss: a promising treatment for obesity in adults with HIV.","volume":"24","author":"Panza","year":"2020","journal-title":"AIDS Behav"},{"key":"R32-20250328","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1089\/aid.2023.0008","article-title":"Weight gain in people with HIV: the role of demographics, antiretroviral therapy, and lifestyle factors on weight.","volume":"39","author":"Patel","year":"2023","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T19:25:22Z","timestamp":1743362722000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041728","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]}}}